Ras-related C3 botulinum toxin substrate 2 (Rac2) (Rac2)

Ras-related C3 botulinum toxin substrate 2 (Rac2) is a small GTPase of the Rho family primarily expressed in hematopoietic cells, where it plays a critical role in leukocyte functions such as chemotaxis, phagocytosis, and the production of reactive oxygen species. In the context of inflammatory diseases like atopic dermatitis and asthma, Rac2 has been identified as a key node in a novel non-kinase inflammatory pathway that regulates the expression of thymic stromal lymphopoietin (TSLP), a master cytokine driving Type 2 inflammation. The drug candidate ENV-294 acts as a first-in-class, non-degrading molecular glue (referred to as a "LOCKTAC") that modulates the interaction between Rac2 and its regulatory partner, RhoGDI. By stabilizing or reconfiguring this complex, the drug resets the cellular immune response and reduces the production of multiple pro-inflammatory cytokines, offering a "pan-endotype" efficacy profile similar to JAK inhibitors but with a safety profile comparable to biologics. This approach represents a paradigm shift from traditional receptor blockade or kinase inhibition toward the precise modulation of intracellular signaling complexes to achieve durable disease modification.

Other names

p21-Rac2Ras-related C3 botulinum toxin substrate 2Novel non-kinase inflammatory pathwayLOCKTAC targetRac2-RhoGDI complex

Non-degrading molecular glue (LOCKTAC) that modulates the interaction between Rac2 and RhoGDI, leading to reduced expression of thymic stromal lymphopoietin (TSLP) and reconfiguration of the cellular immune response.